2023 年度報告

Futu NewsApr 26 04:32 ET · Announcements

JD.com's 1Q Revenue Likely Supported by Low-Price Strategy, Better User Experience -- Market Talk

JD.com's low-price strategy and user experience enhancement likely sustained its gross merchandise value growth momentum and supported 1Q revenue growth, Daiwa analysts John Choi and Robin Leung say in a research note.

WSJApr 16 22:26 ET

[Broker Focus] Tianfeng Securities maintains JD Health (06618) “buy” rating and is optimistic about the continued penetration of active users and the guarantee of omni-channel supply chain capabilities

Jinwu Financial News | According to Tianfeng Securities Research, JD Health (06618) achieved operating revenue of 53.5 billion yuan in 2023, an increase of 14.5% over 46.7 billion yuan in the same period last year; by business, the company's own product revenue in 2023 was 45.65 billion yuan, up 13.1% year on year; service revenue was 7.88 billion yuan, up 23.7% year on year. The company's gross margin increased by 1.0 pct to 22.2%, mainly due to changes in the product portfolio; annual profit was 2.14 billion yuan, up 459.2% year on year, and adjusted non-IFRS net profit reached 4.14 billion yuan, compared with 2

金吾財訊Apr 2 21:22 ET

Nomura Adjusts JD Health's Price Target to HK$44 to HK$37, Keeps at Buy

05:00 AM EDT, 03/22/2024 (MT Newswires) -- Nomura Adjusts JD Health's Price Target to HK$44 to HK$37, Keeps at Buy Price (HKD): $28.05, Change: $-4.05, Percent Change: -12.62%

MT NewswiresMar 22 05:00 ET

JD Health's 2023 Profit Soars Almost Sixfold to Over 2 Billion Yuan

JD Health International (HKG:6618) recorded a nearly sixfold surge in attributable profit for the year ended Dec. 31, 2023, to 2.14 billion yuan from 380.1 million yuan in 2022, a Wednesday filing on

MT NewswiresMar 20 08:11 ET

[Hong Kong Stock Connect] JD Health (06618)'s profit of RMB 2,142 billion last year increased 463.49% year over year

Jinwu Financial News | JD Health (06618) announced that in 2023, the company's shareholders should account for profit of RMB 2,142 billion, an increase of 463.49% over the previous year; basic profit per share was 0.69 yuan. During the period, the company's revenue increased 14.5% from RMB 46.7 billion in 2022 to RMB 53.5 billion in 2023. In detail, the increase in the company's total revenue is mainly due to a 13.1% increase in product revenue from sales of pharmaceuticals and health products from RMB 40.4 billion in 2022 to RMB 45.7 billion in 2023. The main drivers for the growth of commodity revenue are

金吾財訊Mar 20 06:24 ET